ReviewCardiovascular diabetology2023
Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance.
Review in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Dietary interventions in the management of atrial fibrillation.Frontiers in cardiovascular medicine · 2024Pooled it
- Body mass index as a determinant of scar formation post-AF ablation: Insights from DECAAF II.Journal of cardiovascular electrophysiology · 2024Trial
- Association of the chemerin-CMKLR1 with atrial potassium current dysregulation and atrial fibrillation in obese mice.Channels (Austin, Tex.) · 2026Article
- Atrial fibrillation and atrial flutter in China: trends and projections to 2050 from GBD 2023.Internal and emergency medicine · 2026Article
- Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.Cardiovascular drugs and therapy · 2026Article
- Article
- Gut microbiota-activated PLCγ2 monocytes drive atrial fibrillation.Nature communications · 2026Article
- Studies on obesity-related atrial fibrillation in the past 20 years: A bibliometric analysis via CiteSpace and VOSviewer.Medicine · 2026Article
- Smoking and Risk of Atrial Fibrillation Recurrence After Catheter Ablation: A Meta-Analysis and Meta-Regression.Journal of arrhythmia · 2026Article
- SLIT2 and ANGPTL3 as putative mediators linking obesity to atrial fibrillation: A Mendelian randomization study.Medicine · 2026Article
- Article
- A New Paradigm for Atrial Fibrillation Ablation in Obesity Focusing on Substrate Remodeling and Patient-Centered Outcomes.Reviews in cardiovascular medicine · 2026Review
- Circulating RBP4 and FABP4 concentrations in patients with chronic schizophrenia are associated with increased epicardial adipose tissue volume and metabolic syndrome.European archives of psychiatry and clinical neuroscience · 2026Article
- Associations of the triglyceride-glucose index and its obesity-related derivatives with cardiac structure, function, and incident atrial fibrillation: a prospective cohort study using cardiac magnetic resonance.Cardiovascular diabetology · 2026Article
- Association Between HAVOC Score and New-Onset Atrial Fibrillation in Patients With ST-Segment Elevation Myocardial Infarction.Reviews in cardiovascular medicine · 2026Article
- Recent-onset atrial fibrillation: challenges and opportunities.European heart journal · 2026Review
- Development and internal validation of an interpretable machine-learning model for identifying comorbid atrial fibrillation in patients with diabetic kidney disease.Frontiers in clinical diabetes and healthcare · 2026Article
- Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets.Vascular health and risk management · 2026Review
- Reduced Incidence of QTc Prolongation Following Metabolic and Bariatric Surgery in Female Patients: A Retrospective Cohort Study.Obesity surgery · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity and atrial fibrillation (AF), which are inextricably linked, is rapidly increasing worldwide. Obesity rates are higher among patients with AF than healthy individuals. Some epidemiological data indicated that obese patients were more likely to develop AF, but others reported no significant correlation. Obesity-related hypertension, diabetes, and obstructive sleep apnea are all associated with AF. Additionally, increased epicardial fat, systemic inflammation, and oxidative stress caused by obesity can induce atrial enlargement, inflammatory activation, local myocardial fibrosis, and electrical conduction abnormalities, all of which led to AF and promoted its persistence. Weight loss reduced the risk and reversed natural progression of AF, which may be due to its anti-fibrosis and inflammation effect. However, fluctuations in weight offset the benefits of weight loss. Therefore, the importance of steady weight loss urges clinicians to incorporate weight management interventions in the treatment of patients with AF. In this review, we discuss the epidemiology of obesity and AF, summarize the mechanisms by which obesity triggers AF, and explain how weight loss improves the prognosis of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.